Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States

被引：4

作者：

DiNofia, Amanda M. ^{[1
]}

Salazar, Elizabeth ^{[1
]}

Seif, Alix E. ^{[1
,2
]}

Li, Yimei ^{[1
,3
]}

Huang, Yuan-Shung Vera ^{[4
]}

Bagatell, Rochelle ^{[1
,2
]}

Fisher, Brian T. ^{[2
,3
,4
,5
]}

Aplenc, Richard ^{[1
,2
,3
,4
]}

机构：

[1] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA

[2] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA

[3] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA

[4] Childrens Hosp Philadelphia, Ctr Pediat Clin Effectiveness, Philadelphia, PA 19104 USA

[5] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA

来源：

PLOS ONE | 2016年 / 11卷 / 03期

关键词：

PROTEASOME INHIBITOR BORTEZOMIB; ACUTE LYMPHOBLASTIC-LEUKEMIA; ANTIBODY-MEDIATED REJECTION; ONCOLOGY GROUP; PEDIATRIC-PATIENTS; PHASE-I; THERAPEUTIC ADVANCES; CHILDHOOD LEUKEMIA; SOLID TUMORS; TRANSPLANT;

D O I：

10.1371/journal.pone.0151362

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

This study is a pharmacoepidemiologic description of pediatric bortezomib use. Exposure was identified through billing codes in patients admitted to US children's hospitals that participated with the Pediatric Health Information System between 2004 and 2013. Associated information on underlying diseases, demographics, institutional use, mortality, and physician type was collected. Exposure to bortezomib was identified in 314 patients. Hematologist/Oncologists prescribed half of the bortezomib used. Use increased during the study period. Inpatient volume was positively correlated with bortezomib utilization. Bortezomib use in pediatrics is increasing for a variety of diseases. Variation in use exists across institutions. Further studies are needed to characterize bortezomib's efficacy in pediatric diseases.

引用

页数：6

共 18 条

[1]

Blaney SM, 2004, J CLIN ONCOL, V22, P4804, DOI 10.1200/JCO.2004.12.185

[2] Protective immunity and use of bortezomib for antibody-mediated rejection in a pediatric kidney transplant recipient [J].

Claes, Donna J. ;

Yin, Hong ;

Goebel, Jens .

PEDIATRIC TRANSPLANTATION, 2014, 18 (04) :E100-E105

[3]

Garg PP, 2000, J AM SOC NEPHROL, V11, P958, DOI 10.1681/ASN.V115958

[4] A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: A Children's Oncology Group study [J].

Horton, Terzah M. ;

Pati, Debananda ;

Plon, Sharon E. ;

Thompson, Patrick A. ;

Bomgaars, Lisa R. ;

Adamson, Peter C. ;

Ingle, Ashish M. ;

Wright, John ;

Brockman, Adam H. ;

Paton, Martin ;

Blaney, Susan M. .

CLINICAL CANCER RESEARCH, 2007, 13 (05) :1516-1522

[5] A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study [J].

Horton, Terzah M. ;

Drachtman, Richard A. ;

Chen, Lu ;

Cole, Peter D. ;

McCarten, Kathleen ;

Voss, Stephan ;

Guillerman, Robert P. ;

Buxton, Allen ;

Howard, Scott C. ;

Hogan, Shirley M. ;

Sheehan, Andrea M. ;

Lopez-Terrada, Dolores ;

Mrazek, Matthew D. ;

Agrawal, Neeraj ;

Wu, Meng-Fen ;

Liu, Hao ;

De Alarcon, Pedro A. ;

Trippet, Tanya M. ;

Schwartz, Cindy L. .

BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (01) :118-122

[6] A Phase 2 Study of Bortezomib Combined with Either Idarubicin/Cytarabine or Cytarabine/Etoposide in Children with Relapsed, Refractory or Secondary Acute Myeloid Leukemia: A Report from the Children's Oncology Group [J].

Horton, Terzah M. ;

Perentesis, John P. ;

Gamis, Alan S. ;

Alonzo, Todd A. ;

Gerbing, Robert B. ;

Ballard, Jennifer ;

Adlard, Kathleen ;

Howard, Dianna S. ;

Smith, Franklin O. ;

Jenkins, Gaye ;

Kelder, Angele ;

Schuurhuis, Gerrit J. ;

Moscow, Jeffrey A. .

PEDIATRIC BLOOD & CANCER, 2014, 61 (10) :1754-1760

[7] Leveraging Administrative Data to Monitor Rituximab Use in 2875 Patients at 42 Freestanding Children's Hospitals across the United States [J].

Kavcic, Marko ;

Fisher, Brian T. ;

Seif, Alix E. ;

Li, Yimei ;

Huang, Yuan-Shung ;

Walker, Dana ;

Aplenc, Richard .

JOURNAL OF PEDIATRICS, 2013, 162 (06) :1252-U226

[8]

Khandelwal P, 2014, BIOL BLOOD MARROW TR, V20, pS174, DOI 10.1016/j.bbmt.2014.06.032

[9] HLA desensitization with bortezomib in a highly sensitized pediatric patient [J].

May, Lindsay J. ;

Yeh, Justin ;

Maeda, Katsuhide ;

Tyan, Dolly B. ;

Chen, Sharon ;

Kaufman, Beth D. ;

Bernstein, Daniel ;

Rosenthal, David N. ;

Hollander, Seth A. .

PEDIATRIC TRANSPLANTATION, 2014, 18 (08) :E280-E282

[10] Bortezomib for Effective Treatment of a Child With Refractory Autoimmune Hemolytic Anemia Post Allogeneic Hematopoietic Stem Cell Transplant [J].

Mehta, Bhakti ;

Mahadeo, Kris ;

Zaw, Re ;

Tang, Shinyi ;

Kapoor, Neena ;

Abdel-Azim, Hisham .

PEDIATRIC BLOOD & CANCER, 2014, 61 (12) :2324-2325

← 1 2 →